CYP cynata therapeutics limited

Looks like it is easy to put those with different points of view...

  1. 4,161 Posts.
    lightbulb Created with Sketch. 1467
    Looks like it is easy to put those with different points of view in suspension while continuing the lies. A three to four fold increase in the significance of a study due to much larger population being assessed and you still continue with the low N value bull . 11 lots were tested, howmany would you say were needed?

    (we can hold in suspension Bazsa's suggestion that there may be more than one patient per data point - so each of the 11 might be an average - (with 2 patients behind one data point perhaps 3 behind another perhaps all adding up to say 40 at the max (but its less than that though because you can't include subjects who got multiple lots - this is still only single lots (that's written on the slide) I can deal with that later multiples per dot suggestion of Bazsa's later I think)."[

    Are look at the P values, how could they be so different ?
    Glad to see I am not the only one to be put on suspension when the facts get in the way of a good story


    chahttps://hotcopper.com.au/posts/74182160/singlenge?

    "which is the only potential adequate and well controlled study (the FDA is supposed to have at least one for a BLA"

    Well done, that makes 3 piles of bull in one post.

    I really do wish you a good trip to the cliff face.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.0¢
Change
0.000(0.00%)
Mkt cap ! $36.15M
Open High Low Value Volume
16.0¢ 16.5¢ 16.0¢ $15.66K 97.07K

Buyers (Bids)

No. Vol. Price($)
1 36112 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
16.5¢ 55253 4
View Market Depth
Last trade - 14.39pm 26/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.